Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

AI-powered ECG Analysis for Deadly Arrhythmias and ICI Myocarditis

ELDORA is a non-interventional observational data-science study aiming to develop and validate clinical-grade artificial intelligence tools applied to electrocardiogram (ECG) data. The project will standardize heterogeneous ECGs, create the ECGInsight harmonized database, and train interpretable models for life-threatening arrhythmia risk prediction, especially Torsades-de-Pointes/long QT syndrome and immune checkpoint inhibitor (ICI)-induced myocarditis. The project uses existing and ongoing national and international ECG cohorts with de-identified clinical metadata; AI outputs are intended for research/model development and are not used to drive patient care during the study.

Participants needed: 127,000
Trial details
Biological sex: AllType: ObservationalSponsor: Groupe Hospitalier Pitie-SalpetriereUpdated: Jun 12, 2026Locations: 1
Eligibility criteria

subjects included in participating existing or ongoing ECG cohorts made availabl... [+2]

datasets or individual records for which required approvals, data-sharing agreem...

Status: Recruiting

ATROPOS: Survival Analysis of ICI-associated Myocarditis

ATROPOS is an international, registry-based observational study of cancer patients with immune checkpoint inhibitor-associated myocarditis (ICI-M). The study evaluates whether immunosuppressive treatment strategies, including first-line glucocorticoids and subsequent second-line immunosuppressants, are associated with overall mortality, and whether these associations vary according to myocarditis severity. The target number of cases to be included is 1500 spanning from at least 160 centers, located in at least 18 countries. Analyses will adjust for clinically relevant confounders and may use time-dependent survival models where appropriate.

Participants needed: 1,500
Trial details
Biological sex: AllType: ObservationalSponsor: Groupe Hospitalier Pitie-SalpetriereUpdated: Jun 10, 2026Locations: 1
Eligibility criteria

cancer patients exposed to at least one immune checkpoint inhibitor [+3]

duplicate records [+2]